MedTrace Logo

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

NCT03450018 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-05-24

No results posted yet for this study

Summary

This is a multi-center, open-label Phase 1b study of SLC-0111 (oral) in combination with IV gemcitabine in CA IX positive subjects with mPDAC and comprises of 2 parts:

* Part 1: Dose Escalation
* Part 2: Dose Expansion

Conditions

Interventions

DRUG

SLC-0111

Oral SLC-0111

DRUG

Gemcitabine Injection

1000 mg/m\^2 IV

Sponsors & Collaborators

  • Canadian Cancer Society (CCS)

    collaborator OTHER

  • SignalChem Lifesciences Corporation

    collaborator INDUSTRY

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Daniel J Renouf, MD · BC Cancer - Vancouver

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-10
Primary Completion
2024-05-16
Completion
2024-05-16

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03450018 on ClinicalTrials.gov